Assessment of the Anticoagulant Effect of Curcumin as Adjuvant Therapy to Enoxaparinin Covid-19 Iraqi Patients
Maiss S Baqer, Saifan A Dushan, Rafif Raad, Rabab Mohammed Noori Hameed, Ayaashraf Ahmed, Basim Dhawi Dakhil
Medical Forum Monthly, doi:10.60110/medforum.360407
Objective: To assess the anticoagulant effect of curcumin as adjuvant treatment to enoxaparin in COVID-19 patients. Study Design: Randomized open-labelled controlled trial study. Place and Duration of Study: This study was conducted at the College of Pharmacy, Al-Esraa University, Baghdad, Iraq from 1 st February 2020 to 31 st July 2020. Methods: Fifty-eight patients with confirmed Covid19 were enrolled into 2 groups: Group A; 29 patients were given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs. Group B; 29 patients were given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs + Curcumin 500 mg 3 times daily. Results: A significantly higher level of improvement in the outcomes of D-dimer serum level in the group treated with enoxaparin and curcumin in comparison with group A which was treated with enoxaparin alone (P<0.05).
Conclusion: The overall results of this clinical study showed a significant D-dimer reduction by curcumin supplementation as well as reducing mortality and enhancing the overall clinical outcome of the treatment when used as an adjunct to enoxaparin.
CONCLUSION The overall results of this clinical study showed a significant D-dimer reduction by curcumin supplementation. These findings uphold the idea that this polyphenol has the potential in attenuating coagulopathy and mitigate disease severity Moreover, clinical trials with curcumin demonstrated safety, durability, and nontoxicity. Thus, it sounds rational to consider the treatment of COVID-19 and its complications with highly effective nutraceuticals such as curcumin even alone or as an adjunct to other bestknown treatments of it.
Author's Contribution: Concept
References
Astuti, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes & Metabolic Syndrome, Clin Res Rev
Baj, Karakuła-Juchnowicz, Teresiński, Buszewicz, Ciesielka et al., COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge, J Clin Med
Bikdeli, Madhavan, Gupta, Jimenez, Burton et al., Global COVID-19 thrombosis collaborative group. pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research, Thromb Haemost
Chen, Kuo, Chai, Ou, Yang, Pretreatment of curcumin attenuates coagulopathy and renal injury in LPS-induced endotoxemia, J Endotoxin Res
Cheng, Hu, Wang, Huang, Zhao et al., Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients, Int J Antimicrob Agents
Gupta, Patchva, Koh, Aggarwal, Discovery of curcumin, a component of golden spice, and its miraculous biological activities, Clin Exp Pharmacol Physiol
Han, Yang, Liu, Liu, Wu et al., Prominent changes in blood coagulation of patients with SARS-CoV-2 infection, Clin Chem Lab Med
Hermans, Deneys, L'hémostase et la coagulation sanguine revisitées: mécanismes et implications thérapeutiques [Hemostasis and blood coagulation revisited: mechanisms and therapeutic implications, J Pharm Belg
Keihanian, Saeidinia, Bagheri, Johnston, Sahebkar, Curcumin, hemostasis, thrombosis, and coagulation, J Cell Physiol
Khan, Khan, Khan, Nawaz, Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study, J Med Microbiol
Kim, Ku, Bae, Anticoagulant activities of curcumin and its derivative, BMB Rep
Kim, Ku, Bae, Anticoagulant activities of curcumin and its derivative, BMB Rep
Lancet, COVID-19 coagulopathy: an evolving story, Lancet Haematol
Liang, Wang, Chien, Yarmishyn, Yang et al., Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection, Front Immunol
Manoharan, Haridas, Vasanthakumar, Muthu, Thavoorullah et al., Curcumin: a Wonder Drug as a Preventive Measure for COVID19 Management, Indian J Clin Biochem
Mcfadyen, Stevens, Peter, The emerging threat of (Micro) Thrombosis in COVID-19 and its therapeutic implications, Circ Res
Nemmar, Al-Salam, Dhanasekaran, Sudhadevi, Ali, Pulmonary exposure to diesel exhaust particles promotes cerebral microvessel thrombosis: protective effect of a cysteine prodrug l-2-oxothiazolidine-4-carboxylic acid, Toxicol
Nemmar, Subramaniyan, Ali, Protective effect of curcumin on pulmonary and cardiovascular effects induced by repeated exposure to diesel exhaust particles in mice, PLoS One
Panigada, Bottino, Tagliabue, Grasselli, Novembrino et al., Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis, J Thromb Haemost
Pawar, Mastud, Pawar, Pawar, Bhoite et al., Oral curcumin with piperine as adjuvant therapy for the treatment of COVID-19: a randomized clinical trial, Frontiers Pharmacol
Suresh, Curcumin and Coagulopathy in the COVID19 Era, Indian J Clin Biochem
Tang, Li, Wang, Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost
Zhang, Yan, Fan, Liu, Liu et al., D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19, J Thromb Haemost
DOI record:
{
"DOI": "10.60110/medforum.360407",
"ISSN": [
"2519-7134",
"1029-385X"
],
"URL": "http://dx.doi.org/10.60110/medforum.360407",
"abstract": "<jats:p>Objective: To assess the anticoagulant effect of curcumin as adjuvant treatment to enoxaparin in COVID-19 patients. Study Design: Randomized open-labelled controlled trial study. Place and Duration of Study: This study was conducted at the College of Pharmacy, Al-Esraa University, Baghdad, Iraq from 1st February 2020 to 31st July 2020. Methods: Fifty-eight patients with confirmed Covid19 were enrolled into 2 groups: Group A; 29 patients were given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs. Group B; 29 patients were given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs + Curcumin 500 mg 3 times daily. Results: A significantly higher level of improvement in the outcomes of D-dimer serum level in the group treated with enoxaparin and curcumin in comparison with group A which was treated with enoxaparin alone (P<0.05). Conclusion: The overall results of this clinical study showed a significant D-dimer reduction by curcumin supplementation as well as reducing mortality and enhancing the overall clinical outcome of the treatment when used as an adjunct to enoxaparin. </jats:p>",
"author": [
{
"affiliation": [],
"family": "Baqer",
"given": "Maiss S.",
"sequence": "first"
},
{
"affiliation": [],
"family": "Dushan",
"given": "Saifan A",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Raad",
"given": "Rafif",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Noori Hameed",
"given": "Rabab Mohammed",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ahmed",
"given": "Ayaashraf",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Dakhil",
"given": "Basim Dhawi",
"sequence": "additional"
}
],
"container-title": "Medical Forum Monthly",
"container-title-short": "mfm",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2025,
5,
26
]
],
"date-time": "2025-05-26T19:26:24Z",
"timestamp": 1748287584000
},
"deposited": {
"date-parts": [
[
2025,
5,
26
]
],
"date-time": "2025-05-26T19:29:56Z",
"timestamp": 1748287796000
},
"indexed": {
"date-parts": [
[
2025,
5,
26
]
],
"date-time": "2025-05-26T20:10:09Z",
"timestamp": 1748290209227,
"version": "3.41.0"
},
"is-referenced-by-count": 0,
"issue": "4",
"issued": {
"date-parts": [
[
2025,
4,
30
]
]
},
"journal-issue": {
"issue": "4",
"published-online": {
"date-parts": [
[
2025,
5,
26
]
]
}
},
"link": [
{
"URL": "http://medicalforummonthly.com/index.php/mfm/article/download/5253/4728",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "http://medicalforummonthly.com/index.php/mfm/article/download/5253/4728",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "39730",
"original-title": [],
"prefix": "10.60110",
"published": {
"date-parts": [
[
2025,
4,
30
]
]
},
"published-online": {
"date-parts": [
[
2025,
4,
30
]
]
},
"publisher": "Medical Academic Foundation",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "http://medicalforummonthly.com/index.php/mfm/article/view/5253"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Assessment of the Anticoagulant Effect of Curcumin as Adjuvant Therapy to Enoxaparinin Covid-19 Iraqi Patients",
"type": "journal-article",
"volume": "36"
}
